NASDAQ:SLS SELLAS Life Sciences Group (SLS) Stock Price, News & Analysis → Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press) (Ad) Free SLS Stock Alerts $1.50 +0.05 (+3.45%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$1.47▼$1.7050-Day Range$1.21▼$1.6352-Week Range$0.50▼$1.91Volume4.06 million shsAverage Volume635,887 shsMarket Capitalization$86.64 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get SELLAS Life Sciences Group alerts: Email Address SELLAS Life Sciences Group MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside100.0% Upside$3.00 Price TargetShort InterestBearish13.24% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.78Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.75) to ($0.57) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.00 out of 5 starsMedical Sector787th out of 915 stocksPharmaceutical Preparations Industry369th out of 430 stocks 3.5 Analyst's Opinion Consensus RatingSELLAS Life Sciences Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageSELLAS Life Sciences Group has received no research coverage in the past 90 days.Read more about SELLAS Life Sciences Group's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.24% of the outstanding shares of SELLAS Life Sciences Group have been sold short.Short Interest Ratio / Days to CoverSELLAS Life Sciences Group has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in SELLAS Life Sciences Group has recently increased by 5.52%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSELLAS Life Sciences Group does not currently pay a dividend.Dividend GrowthSELLAS Life Sciences Group does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SLS. Previous Next 2.7 News and Social Media Coverage News SentimentSELLAS Life Sciences Group has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for SELLAS Life Sciences Group this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for SLS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows6 people have added SELLAS Life Sciences Group to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SELLAS Life Sciences Group insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.60% of the stock of SELLAS Life Sciences Group is held by insiders.Percentage Held by InstitutionsOnly 17.38% of the stock of SELLAS Life Sciences Group is held by institutions.Read more about SELLAS Life Sciences Group's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for SELLAS Life Sciences Group are expected to grow in the coming year, from ($0.75) to ($0.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SELLAS Life Sciences Group is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SELLAS Life Sciences Group is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about SELLAS Life Sciences Group's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About SELLAS Life Sciences Group Stock (NASDAQ:SLS)SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.Read More SLS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLS Stock News HeadlinesJune 14 at 8:39 AM | americanbankingnews.comStock Traders Purchase Large Volume of SELLAS Life Sciences Group Call Options (NASDAQ:SLS)June 10, 2024 | globenewswire.comSELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AMLMay 22, 2024 | finance.yahoo.comCan SELLAS Life Sciences Group (NASDAQ:SLS) Afford To Invest In Growth?May 17, 2024 | markets.businessinsider.comStrong Buy Rating on SELLAS Life Sciences Amid Progress in AML Treatment PipelineMay 14, 2024 | msn.comSLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q1 2024May 14, 2024 | globenewswire.comSELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 7, 2024 | seekingalpha.comSLS SELLAS Life Sciences Group, Inc.May 3, 2024 | msn.comSamsung's Life Science Fund invests in Seattle's Latus BioMay 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: SELLAS Life Sciences Group (SLS) and NovoCure (NVCR)May 1, 2024 | msn.comSellas reports positive Phase 2 data from AML study, files for patentMay 1, 2024 | markets.businessinsider.comSELLAS Reports Positive Phase 2 Preliminary Data With SLS009May 1, 2024 | globenewswire.comSELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose LevelApril 29, 2024 | globenewswire.comSELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 StudyApril 27, 2024 | msn.comMahindra Lifespace's FY24 Profit Inches Down to Rs 98 Crore Amidst Record Sale Bookings of Rs 2,328 CroreApril 19, 2024 | seekingalpha.comSellas Life Sciences Group: A Lottery Ticket With An Estimated 9x PayoutMarch 28, 2024 | msn.comSELLAS Life Sciences Group files for $200M mixed shelfMarch 28, 2024 | globenewswire.comSELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 27, 2024 | markets.businessinsider.comBuy Rating for SELLAS Life Sciences Amid Positive AML Study Results and Strengthened FinancialsMarch 26, 2024 | markets.businessinsider.comSELLAS Phase 2a Study Of SLS009 In R/r AML Positive; Updates Phase 3 REGAL StudyMarch 26, 2024 | globenewswire.comSELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL StudyMarch 21, 2024 | wsj.comSELLAS Life Sciences Group Inc.March 19, 2024 | globenewswire.comSELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesMarch 19, 2024 | globenewswire.comSELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ETMarch 16, 2024 | marketwatch.comSellas Life Sciences Shares Drop 31% After Direct Offering PricesMarch 15, 2024 | msn.comGeron, Graphite Bio, Immuneering among healthcare moversSee More Headlines Receive SLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SELLAS Life Sciences Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/15/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SLS CUSIPN/A CIK1390478 Webwww.sellaslifesciences.com Phone(646) 200-5278Fax441-400-2875Employees17Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside+100.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-5,258.30% Return on Assets-249.95% Debt Debt-to-Equity RatioN/A Current Ratio1.49 Quick Ratio1.49 Sales & Book Value Annual Sales$1 million Price / Sales86.64 Cash FlowN/A Price / Cash FlowN/A Book Value($0.25) per share Price / Book-6.00Miscellaneous Outstanding Shares57,760,000Free Float56,831,000Market Cap$86.64 million OptionableNot Optionable Beta2.11 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Angelos M. Stergiou M.D. (Age 48)ScD h.c., Founder, President, CEO & Director Comp: $921.99kMr. John Thomas Burns CPA (Age 39)Senior VP & CFO Comp: $338.45kMs. Stacy E. YeungVP, Associate General Counsel & Head of ComplianceDr. Dragan Cicic M.D. (Age 61)MBA, Senior Vice President of Clinical Development Comp: $466.43kMr. Andrew ElnatanVP and Head of Regulatory Affairs, Chemistry, Manufacturing and Controls & QualityKey CompetitorsEledon PharmaceuticalsNASDAQ:ELDNNeos TherapeuticsNASDAQ:NEOSCellectar BiosciencesNASDAQ:CLRBCorrevio PharmaNASDAQ:CORVAlto NeuroscienceNYSE:ANROView All CompetitorsInstitutional OwnershipVirtu Financial LLCSold 20,485 shares on 5/20/2024Ownership: 0.068%Anson Funds Management LPBought 4,832,368 shares on 5/14/2024Ownership: 8.366%Opus Capital Group LLCBought 65,600 shares on 4/26/2024Ownership: 0.356%View All Institutional Transactions SLS Stock Analysis - Frequently Asked Questions Should I buy or sell SELLAS Life Sciences Group stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SELLAS Life Sciences Group in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SLS shares. View SLS analyst ratings or view top-rated stocks. What is SELLAS Life Sciences Group's stock price target for 2024? 1 Wall Street research analysts have issued 1-year price objectives for SELLAS Life Sciences Group's stock. Their SLS share price targets range from $3.00 to $3.00. On average, they predict the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 100.0% from the stock's current price. View analysts price targets for SLS or view top-rated stocks among Wall Street analysts. How have SLS shares performed in 2024? SELLAS Life Sciences Group's stock was trading at $1.06 at the beginning of the year. Since then, SLS shares have increased by 41.5% and is now trading at $1.50. View the best growth stocks for 2024 here. When is SELLAS Life Sciences Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our SLS earnings forecast. How were SELLAS Life Sciences Group's earnings last quarter? SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) issued its earnings results on Tuesday, May, 14th. The company reported ($0.21) EPS for the quarter. What ETFs hold SELLAS Life Sciences Group's stock? ETFs with the largest weight of SELLAS Life Sciences Group (NASDAQ:SLS) stock in their portfolio include Sprott Junior Copper Miners ETF (COPJ).Global X Copper Miners ETF (COPX). When did SELLAS Life Sciences Group's stock split? Shares of SELLAS Life Sciences Group reverse split on Friday, November 8th 2019. The 1-50 reverse split was announced on Wednesday, November 6th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 7th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. Who are SELLAS Life Sciences Group's major shareholders? SELLAS Life Sciences Group's stock is owned by many different institutional and retail investors. Top institutional investors include Anson Funds Management LP (8.37%), Opus Capital Group LLC (0.36%) and Virtu Financial LLC (0.07%). View institutional ownership trends. How do I buy shares of SELLAS Life Sciences Group? Shares of SLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SLS) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SELLAS Life Sciences Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SELLAS Life Sciences Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.